Leukemia inhibitory factor (LIF) is a cytokine which belongs to the IL-6 superfamily. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells and immune tolerance at the maternal-fetal interface. LIF action appears to be mediated through a high-affinity receptor complex composed of a low-affinity LIFR and a high-affinity converter subunit, gp130.

Despite LIF is identified as a myeloid leukemia-differentiation-inducing factor, it has surprisingly few effects on haematopoietic cells. Recently years, increasing studies have implied that LIF also has a powerful function in cancer, such as pancreatic and breast cancer. Read More>>

CUSABIO, as a manufacturer of active proteins, has developed recombinant human LIF and LIFR protein with high quality to fuel anti-tumor drug development.

Featured Products

• Recombinant Human LIF (Active) (CSB-MP012928HUd9)

Purity>90% (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Activity validated by functional ELISA Immobilized human LIF at 2 μg/ml can bind human LIFR (CSB-MP012929HUi9), the EC50 is 22.58-30.24 ng/ml.

• Recombinant Human LIFR, partial (Active) (CSB-MP012929HUi9)

Purity>95% (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Activity validated by functional ELISA Immobilized human LIF (CSB-MP012928HU) at 2 μg/ml can bind human LIFR, the EC50 is 11.68-15.52 ng/ml.

If you can't find the protein you desired, you can contact us to customize.